Search
Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL.
Kids born with Down syndrome are at high risk of an array of health problems. One of the lesser-known complications is their increased risk of childhood leukaemia.
Dr Laurence Cheung is doing everything he can to end the threat of childhood leukemia. His research has the potential to change countless lives, but he also has another important job – being a dad to three beautiful children.
Functional role of CTGF in altering disease progression in a lymphoid malignancy
Biological changes associated with T-ALL relapse and resistance are stochastic and highly individual
Identified CCI-007 as a novel small molecule that displays rapid toxicity towards a subset of MLL-r, CALM-AF10 and SET-NUP214 leukemia cell lines
We report a term male with congenital acute erythroleukemia who achieved sustained remission with low-dose cytosine arabinoside alone
Present a valuable resource for drug discovery and have identified ROM as a promising therapeutic for MLL-rearranged iALL
Haematological malignancies, although a broad range of specific disease types, continue to show considerable overlap in classification, and patients are...
Connective tissue growth factor (CTGF/CCN2) has been shown previously to be aberrantly expressed in a high proportion of paediatric precursor B cell acute...